PGEN
HealthcarePrecigen, Inc. · Biotechnology · $1B
What is Precigen, Inc.?
Precigen, Inc. is a clinical-stage biotechnology company focused on discovering and developing next-generation gene and cellular therapies. Headquartered in Germantown, the company targets cancer and other serious diseases.
Precigen generates revenue primarily through collaboration and licensing agreements while advancing its proprietary therapy platforms. The company engineers genetic components, immune cell therapies, and gene delivery systems. It also provides genetically engineered swine for regenerative medicine and reproductive technologies, broadening its reach beyond oncology.
Precigen was established in 2013 and is headquartered in Germantown, US.
- UltraCAR-T platform for cancer immunotherapy
- AdenoVerse Immunotherapy gene delivery technology
- ActoBiotics mucosal protein delivery platform
- RheoSwitch inducible gene regulation system
Is PGEN a Good Stock to Buy?
UQS Score rates PGEN as Below Average overall.
The Growth, Risk, and Valuation pillars each carry a Good label, suggesting the pipeline trajectory and current pricing profile are relatively favorable for a clinical-stage biotech. Risk is rated Good, which is notable given the inherent uncertainty in gene therapy development.
Quality and Moat are both rated Weak, reflecting limited commercial revenue and an early-stage competitive position.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account on UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PGEN pay dividends?
No — Precigen, Inc. does not currently pay a dividend.
Precigen does not pay a dividend. As a clinical-stage company, available capital is directed toward research, platform development, and advancing its therapy pipeline — a common approach for early-stage biotechs prioritizing growth over income distribution.
When does PGEN report earnings?
Precigen reports earnings on a quarterly cadence, consistent with US-listed public companies.
As a pre-commercial biotech, Precigen's quarterly results are closely watched for pipeline milestones and collaboration revenue rather than traditional profitability metrics. Progress on clinical programs and licensing activity tend to drive market reaction.
For the most recent quarter's results, visit Precigen's investor relations page directly.
PGEN Price History
-39.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Precigen, Inc.?
Based on Precigen, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Precigen do?
Precigen discovers and develops gene and cellular therapies, primarily targeting cancer. Its platforms include UltraCAR-T for immune cell engineering, AdenoVerse for gene delivery, and ActoBiotics for mucosal protein delivery. The company also licenses its technologies through collaboration agreements.
Does PGEN pay dividends?
No, Precigen does not pay a dividend. The company reinvests available resources into its clinical programs and platform development, which is typical for early-stage biotechnology companies without commercial-stage products generating consistent revenue.
When does PGEN report earnings?
Precigen reports on a standard quarterly schedule. For the exact timing of upcoming releases, check Precigen's investor relations page, as our data source does not cover specific future earnings dates.
Is PGEN a good stock to buy?
UQS Score rates PGEN as Below Average overall. While Growth, Risk, and Valuation pillars are rated Good, the Weak Quality and Moat ratings highlight meaningful challenges. The complete pillar breakdown is available to Pro members on UQS Score.
Is PGEN overvalued?
PGEN's Valuation pillar is rated Good within the UQS framework, suggesting the current pricing is not considered elevated relative to its profile. For the full valuation metrics behind this rating, a Pro account provides the detailed breakdown.
What is PGEN's market cap bracket?
Precigen is classified as a small-cap company. This places it among smaller publicly traded biotechs, where pipeline outcomes and partnership developments tend to have an outsized influence on market valuation.
Is PGEN a long-term quality investment?
As a long-term quality indicator, PGEN's Below Average UQS Score reflects current weaknesses in Quality and Moat. The Good Growth rating suggests pipeline potential, but investors focused on long-term quality may want to monitor commercial progress before drawing conclusions.
What sector does PGEN belong to?
Precigen operates in the Healthcare sector, specifically within clinical-stage biotechnology. Its focus on gene and cellular therapy places it in one of the more research-intensive and capital-demanding areas of the broader healthcare industry.
Unlock Full PGEN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare PGEN against sector peers with side-by-side scoring
- ✓Get the complete analyst-style view available to Pro members
Pro Analysis
PGEN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 37.3 | 0.8 | 10.0 | 70.0 | 58.8 | 78.2 | +1.4 |
| May 14, 2026 | 35.9 | 17.5 | 10.0 | 70.0 | 35.3 | 65.2 | -1.7 |
| May 12, 2026 | 37.6 | 0.8 | 10.0 | 70.0 | 74.4 | 64.9 | +0.1 |
| May 7, 2026 | 37.5 | 0.8 | 10.0 | 70.0 | 74.4 | 64.1 | -0.2 |
| May 3, 2026 | 37.7 | 0.8 | 10.0 | 70.0 | 74.4 | 65.5 | 0.0 |
| Apr 26, 2026 | 37.7 | 0.8 | 10.0 | 70.0 | 74.4 | 65.3 | -0.1 |
| Apr 19, 2026 | 37.8 | 0.8 | 10.0 | 70.0 | 74.4 | 66.0 | +0.2 |
| Apr 12, 2026 | 37.6 | 0.8 | 10.0 | 70.0 | 74.4 | 65.1 | -0.2 |
| Apr 2, 2026 | 37.8 | 0.8 | 10.0 | 70.0 | 74.4 | 66.3 | — |
PGEN — Pillar Breakdown
Quality
— 0.8/100 (25%)Precigen, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 70.0/100 (20%)Precigen, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 58.8/100 (15%)Precigen, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 78.5/100 (15%)Precigen, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 10/100 (25%)Precigen, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PGEN.
Score Composition
Financial Data
More Stock Analysis
How is the PGEN UQS Score Calculated?
The UQS (Unified Quality Score) for Precigen, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Precigen, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Precigen, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.